千红制药(002550) - 2020 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2020 was ¥145,850,292.12, a decrease of 60.22% compared to ¥366,672,534.19 in the same period last year[8] - The net profit attributable to shareholders was -¥25,354,444.81, representing a decline of 128.37% from ¥89,366,258.70 year-on-year[8] - Basic earnings per share were -¥0.0211, a decrease of 130.01% compared to ¥0.0703 in the same period last year[8] - The net profit after deducting non-recurring gains and losses was -¥31,312,327.41, a decline of 153.15% from ¥58,918,033.69 year-on-year[8] - The net profit for the current period is a loss of CNY 27,333,471.34, compared to a profit of CNY 86,679,216.33 in the previous period[70] - The total comprehensive income for the current period is -¥15,397,627.08, compared to ¥95,110,179.33 in the previous period[79] Cash Flow - The net cash flow from operating activities was -¥11,938,804.90, down 114.99% from ¥79,670,053.96 in the previous year[8] - The cash flow from operating activities shows a net outflow of -¥11,938,804.90, contrasting with a net inflow of ¥79,670,053.96 in the previous period[84] - The net cash flow from operating activities was -13,495,368.07, a significant decrease compared to 84,220,171.84 from the previous period, indicating a decline in operational efficiency[88] - Cash inflow from investment activities totaled 404,477,403.86, a substantial increase from 195,279,780.70 in the prior period, reflecting strong investment recovery efforts[90] - The net cash flow from financing activities was -51,915,605.57, worsening from -41,162,266.69 in the previous period, suggesting increased financial strain[90] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,782,930,109.57, a decrease of 5.16% from ¥2,934,287,067.26 at the end of the previous year[8] - The company's total assets amounted to approximately ¥2.78 billion, a decrease from ¥2.93 billion as of December 31, 2019, reflecting a decline of about 5.1%[56] - The company's total liabilities decreased to approximately ¥461.77 million from ¥601.65 million, a reduction of about 23.3%[51] - The total current liabilities were CNY 522,054,917.86, with employee compensation payable at CNY 38,694,479.20[102] - The total liabilities and equity combined amounted to CNY 2,975,919,423.38[105] Shareholder Information - The company's net assets attributable to shareholders were ¥2,322,363,248.99, a slight decrease of 0.41% from ¥2,331,861,745.64 at the end of the previous year[8] - The top shareholder, Wang Yaofang, holds 19.95% of the shares, with a total of 255,402,000 shares[13] - The equity attributable to shareholders of the parent company was approximately ¥2.32 billion, slightly down from ¥2.33 billion, a decrease of about 0.6%[55] Operational Metrics - Operating revenue decreased by 60.22% year-on-year, primarily due to reduced sales affected by the pandemic[24] - Operating costs decreased by 62.53% year-on-year, mainly due to reduced sales as a result of the pandemic[24] - The company reported a gross profit margin of approximately -18.5% for the current period, compared to a positive margin in the previous period[70] Investment and R&D - Research and development expenses for the current period are CNY 13,111,602.52, compared to CNY 14,587,892.62 in the previous period, showing a decrease of 10.1%[67] - The research and development expenses for the current period are ¥8,595,942.45, slightly down from ¥8,638,491.01 in the previous period[74] Legal and Compliance - The company is currently involved in litigation regarding trust financial contract disputes with Anxin Trust Co., Ltd.[25] - The company has not undergone an audit for the first quarter report[106] - The company is implementing new revenue and leasing standards starting from 2020, with no retrospective adjustments made to prior period data[105]